Kisspeptin vs PT-141
Both have been studied in hypoactive sexual desire disorder, but only one cleared the FDA. Kisspeptin remains an early-phase research tool with no approved use.
Kisspeptin
A real hormone atop the reproductive axis with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.
Full Kisspeptin evidence reviewPT-141
Bremelanotide / Vyleesi
FDA-approved as Vyleesi for HSDD in premenopausal women, with phase-3 evidence — but the off-label use in men and at higher doses goes beyond what's proven.
Full PT-141 evidence reviewSide by side
| Kisspeptin | PT-141 | |
|---|---|---|
| Marketed for | Libido, testosterone | Libido, sexual dysfunction |
| Evidence grade | Clinical data | FDA-approved |
| Family | Sexual / melanocortin | Sexual / melanocortin |
| Regulatory status | Not FDA-approved | FDA-approved |
| How it's obtained | Research-only | Compounded |
| Key human source | Thurston, JAMA Netw Open 2022 | RECONNECT phase 3, Obstet Gynecol 2019 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
PT-141 (bremelanotide) is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women, on two placebo-controlled phase 3 trials, with a documented side-effect profile led by nausea plus a transient blood-pressure rise. Kisspeptin has genuine academic human research, including LH-stimulation studies in men and Imperial College brain-imaging work, and a 2022 randomized trial in women with hypoactive sexual desire disorder that measured sexual-response brain activity, but no regulator has approved it and there is no established dose, route, or long-term safety record for the marketed products. The two were studied separately, never against each other.
Kisspeptin fits if
Kisspeptin is worth following as reproductive-axis science, so long as you treat the products sold from it as extrapolations, not a therapy.
PT-141 fits if
PT-141 is the only one of the pair with an approved use, and only for premenopausal women with acquired, generalized HSDD.